We’re proud to announce that Seva has been selected by the U.S. Food and Drug Administration (FDA) to participate in the Total Product Life Cycle Advisory Program (TAP) Pilot. TAP is a voluntary program designed to facilitate more efficient development and approval of medical devices.
Photo of a Pristine 5.0 retina camera in Ukraine donated by Seva.
Since 2017, Seva has worked in Ukraine to address critical eye health needs, including preventing Retinopathy of Prematurity (ROP) in children – the leading cause of blindness among Ukrainian children – and treating CMV retinitis in patients with HIV/AIDS.
Technology allows us to look inequity in the eye and level the playing field. When combined with compassion, it transforms the lives of people thousands of miles away with a simple click of a button.
Sadly, vision impairment continues to rob millions of people every year of a promising future. At Seva we know that this is a solvable public health crisis. 90% of all vision loss is preventable and treatable. Our research validates that investing in eye health improves overall wellbeing, community participation, and economic outlook for families.